Policy

Costs of potentially avoidable complications have significantly more variation than costs of typical care in selected chronic and procedural episodes.

As the FDA continues to work on the biosimilars approval process, there are growing concerns that a true cost-savings can't be realized.

Dr. Jonathan Meyer discusses the importance of prescribing the most appropriate medications for schizophrenia patients.

Healthcare costs are elevated for patients on chronic opioid therapy; nonadherence to the opioid regimen, based on urine drug monitoring results, further increases costs.